Piper Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $7 from $6 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies’ Q3 2024 Financial Performance Overview
- Adaptive Biotechnologies reports Q3 EPS (22c), consensus (29c)
- Adaptive Biotechnologies sees FY MRD business revenue $143 M-$145M
- Adaptive Biotechnologies receives expanded Medicare coverage of clonoSEQ
- Adaptive Biotechnologies price target raised to $8 from $7 at BTIG